Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 5/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7239832 | 0.89 | SRD5A1 (0.48) | TDP1SRD5A1SRD5A2CTSLCTSB | |
| SCHEMBL20944792 | 0.82 | RXRA (0.48) | TDP1RXRATACR1 | |
| SCHEMBL16312476 | 0.74 | TDP1 (0.60) | TDP1RXRA | |
| SCHEMBL20944803 | 0.73 | NTRK1 (0.52) | TDP1RXRA | |
| SCHEMBL4449715 | 0.72 | TDP1 (0.44) | TDP1RXRAHTT | |
| SCHEMBL19450185 | 0.71 | CTSV (0.56) | SRD5A1SRD5A2CTSLCTSVSMN1; SMN2 | |
| SCHEMBL20944805 | 0.71 | TDP1 (0.49) | TDP1RXRA | |
| SCHEMBL20944809 | 0.71 | TDP1 (0.49) | TDP1RXRA | |
| SCHEMBL4459616 | 0.70 | EPHX2 (0.44) | TDP1RXRATACR1SMN1; SMN2 | |
| SCHEMBL20944823 | 0.68 | ALDH1A1 (0.49) | RXRAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230204593-A1 | MICROVESICLE HISTONE H2AX AS A BIOMARKER FOR GENOTOXIC STRESS | PIOMA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-11513125-B2 | Microvesicle histone H2AX as a biomarker for genotoxic stress | PIOMA, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-2971282-B1 | MICROVESICLE HISTONE H2AX AS A BIOMARKER FOR GENOTOXIC STRESS | PIOMA INC (US) | 2018-09-19 | — | — | EP | disclosed |
| US-20160041175-A1 | MICROVESICLE HISTONE H2AX AS A BIOMARKER FOR GENOTOXIC STRESS | PIOMA, INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2050452-A1 | indenoisoquinolines as topoisomerase inhibitors I useful as antineoplastic agents | Purdue Research Foundation (US) | 2009-04-22 | — | — | EP | disclosed |
| US-6509344-B1 | A method for treating a patient having cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 1, whereupon said patient is treated for cancer, and wherein the cancer is | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-01-21 | — | — | US | disclosed |